Human Apolipoprotein C3 ELISA , APOC3
- Known as:
- Human Apolipoprotein C3 Enzyme-linked immunosorbent assay test , APOC3
- Catalog number:
- E01A0516
- Product Quantity:
- 96 Tests/kit
- Category:
- -
- Supplier:
- BGene
- Gene target:
- Human Apolipoprotein C3 ELISA APOC3
Related genes to: Human Apolipoprotein C3 ELISA , APOC3
- Gene:
- APOC3 NIH gene
- Name:
- apolipoprotein C3
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 11q23.3
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-04-26
Related products to: Human Apolipoprotein C3 ELISA , APOC3
Related articles to: Human Apolipoprotein C3 ELISA , APOC3
- Hypertriglyceridaemia is a major risk factor and rising aetiology for acute pancreatitis (AP), a condition associated with significant morbidity and mortality. Novel triglyceride-lowering therapies targeting key regulators of lipoprotein metabolism, specifically apolipoprotein C-III (APOC3), angiopoietin-like 3 protein (ANGPTL3) and angiopoietin-like 4 protein (ANGPTL4), have shown promise in reducing triglyceride levels. This study aims to evaluate the efficacy and safety of APOC3, ANGPTL3 and ANGPTL4 inhibitors for reducing the episodes of AP in patients with hypertriglyceridaemia. - Source: PubMed
Publication date: 2026/08/14
Wu YongziLiu ShiyuLuo WenjuanRao JingwenHe WenhuaWindsor JohnSutton RobertMukherjee RajarshiShi NaHuang Wei - Dyslipidemia is a major driver of atherosclerotic cardiovascular disease, with elevated low-density lipoprotein cholesterol (LDL-C) and triglycerides playing key roles in disease progression. Although conventional lipid-lowering therapies such as statins, ezetimibe, bempedoic acid, and proprotein convertase subtilisin/kexin type 9 inhibitors are effective, their impact is often limited by lifelong treatment requirements, suboptimal adherence, and inadequate achievement of lipid targets, particularly in patients with inherited disorders such as familial hypercholesterolemia. Recent advances in gene-based therapies have introduced a paradigm shift by targeting lipid metabolism at its genetic and molecular basis. Techniques including CRISPR-Cas9 gene editing, small interfering RNA, and antisense oligonucleotides enable precise modulation of key genes such as , , , and , leading to sustained reductions in atherogenic lipids. These therapies act upstream at the level of gene expression or mRNA, offering improved specificity, longer duration of action, and the potential for infrequent or single-dose administration. Clinical and translational studies demonstrate significant lipid-lowering efficacy across multiple pathways, including LDL-C, triglycerides, and lipoprotein(a), addressing previously unmet therapeutic needs. Despite their promise, important challenges remain, including long-term safety concerns, off-target effects, cost, ethical considerations, and regulatory complexities. Emerging strategies such as combination gene targeting and personalized genomic therapy further expand therapeutic potential while supporting a transition toward preventive cardiology. Overall, gene-based therapies represent a transformative approach in lipid management, with the potential to overcome the limitations of conventional treatments and enable durable, precision-based cardiovascular risk reduction. - Source: PubMed
Publication date: 2026/07/11
Manoria Prabhash C - Inter-individual variability in lipid response to dietary modification highlights the critical need for precision nutrition. Current evidence remains fragmented, relying predominantly on restricted candidate-gene studies rather than comprehensive genomic approaches. To bridge this gap, we applied a biologically informed analytical framework to whole-exome sequencing (WES) data to evaluate the nutrigenetics of lipid response in an underrepresented Georgian cohort. Specifically, we explored whether exome-wide and pathway-aggregated genetic variation may contribute to inter-individual differences in LDL cholesterol (ΔLDL-C) and triglyceride (ΔTAG) response to Mediterranean-style dietary guidance. - Source: PubMed
Publication date: 2026/07/16
Iordanishvili SabaChiradze NazibrolaAgladze DodoKikvidze MarineKhuchua ZazaLagani VincenzoSolomonia Revaz - This study elucidates the biochemical mechanisms by which extreme high-altitude environments are associated with the remodeling of the skeletal muscle flavor profile in sheep. Using Bayinbuluke (high-altitude) and Turpan Black (low-altitude) sheep, we integrated volatilomics, metabolomics, transcriptomics, and proteomics to map flavor precursor networks. Odor activity value analysis revealed that high-altitude meat exhibited sub-threshold suppression of animal off-flavors, such as p-cresol, while significantly amplifying premium fruity esters. Targeted metabolomics attributed this sensory inversion to a structural shift in the precursor pool, specifically the enrichment of highly reactive polyunsaturated fatty acids, L-cysteine, and rhamnose. Multi-omics integration demonstrated that cold and hypoxic stresses are associated with metabolic reprogramming. The synergistic downregulation of the gene and APOC3 protein was associated with redirected lipid flux, suggesting a mechanism for functional fatty acid accumulation. Simultaneously, the pronounced upregulation of the gene, potentially driven by antioxidant defense needs, coincided with substantial L-cysteine accumulation. Correlation networks suggested that this precursor shift is negatively correlated with off-flavor generation, possibly via competitive thermal degradation. In conclusion, extreme ecological stress is associated with convergent metabolic reprogramming, contributing to the reconstruction of the flavor precursor pool to alter the characteristic lipid aroma of plateau meat. While these findings provide a comprehensive structural blueprint of plateau meat characteristics, the proposed mechanisms remain hypothetical and warrant future functional and sensory validation. - Source: PubMed
Publication date: 2026/07/16
Yang YalingLiu WujunCao Hang - Lipoproteins are molecules composed of phospholipids and apolipoproteins that transport triacylglycerol and cholesterol in blood and are implicated in the development of many diseases. - Source: PubMed
Publication date: 2026/07/14
Łukaszuk BartłomiejChabowski AdrianZiemba AndrzejChoromańska BarbaraMyśliwiec PiotrSupruniuk KatarzynaMikłosz Agnieszka